Download Files:
Products Details
Product Description
– ACT-777991 is an orally active and selective CXCR3 antagonist. ACT-777991 has microsomes and hepatocytes stability across animal models. ACT-777991 inhibits the migration of activated T cells toward CXCL11[1].
Web ID
– HY-149055
Shipping
– Room temperature
Applications
– COVID-19-immunoregulation
Molecular Formula
– C20H20F6N8O2S
References
– [1]Meyer EA, et al. Discovery of Clinical Candidate ACT-777991, a Potent CXCR3 Antagonist for Antigen-Driven and Inflammatory Pathologies. J Med Chem. 2023 Mar 23;66(6):4179-4196.
CAS Number
– 1967811-46-6
Molecular Weight
– 550.48
SMILES
– OCC[C@@H](N(C(CN1C=NC(C)=N1)=O)CC2)CN2C(SC(C(F)(F)F)=N3)=C3C4=CN=C(C(F)(F)F)N=C4
Clinical Information
– Phase 1
Research Area
– Inflammation/Immunology
Solubility
– 10 mM in DMSO
Target
– CXCR
Isoform
– CXCR3
Pathway
– GPCR/G Protein;Immunology/Inflammation
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
